MedTrace Logo

The Effect of MK0633 in Patients With Chronic Asthma (0633-007)

NCT00404313 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 688

Last updated 2015-10-20

No results posted yet for this study

Summary

A clinical study to evaluate the efficacy and safety of MK0633 in adult patients with chronic asthma.

Conditions

Interventions

DRUG

MK0633

Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633

DRUG

Comparator: placebo

Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00404313 on ClinicalTrials.gov